selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development
Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022 – selectION, Inc., a biopharmaceutical company developing novel peptide therapies…
Read More